PharmEasy-Owned Thyrocare’s Q4 Profit Jumps 25.6% To INR 21.6 Cr

PharmEasy-owned diagnostics platform Thyrocare’s consolidated net profit zoomed 25.6% to INR 21.6 Cr in the fourth quarter of the financial year ended March 2025 (Q4 FY25) from INR 17.2 Cr in the year-ago quarter.

Sequentially, profit increased 14% from INR 18.95 Cr. 

Meanwhile, the company’s consolidated operating revenue grew 21.3% to INR 187.2 Cr during the quarter under review from INR 154.3 Cr in Q4 FY24. The topline rose 12.8% quarter-on-quarter (QoQ) from INR 165.9 Cr. 

Thyrocare’s total revenue, including other income, rose 21.8% to INR 191.8 Cr in the March quarter from INR 157.4 Cr in the year-ago period.

The company earned 63% of its revenue via franchise network, while the rest came from partnerships. The number of active franchises stood at 11,249 at the end of the quarter, up over 16% from 9,696 a year ago. 

In an investor presentation, the company said that its labs grew to 29 in Q4 FY25 from 25 in the previous year. The number of patients rose about 11% to 16.7 Mn during the quarter under review from 15.1 Mn in the year-ago period.

Total expenses for the quarter under review shot up 6.9% to INR 143.9 Cr from INR 134.6 Cr in the same period of previous year. Sequentially, it rose 1.4% from INR 141.9 Cr. 

For the entire FY25, the company saw a 20.2% growth in its operating revenue to INR 687.4 Cr from INR 571.9 Cr in FY24. Meanwhile, net profit zoomed 30.6% to INR 90.8 Cr from INR 69.5 Cr in FY24. 

Founded in 1996 by A. Velumani, Thyrocare is a diagnostic and preventive healthcare company that focusses on providing affordable and high-quality laboratory services. The company’s main focus is on clinical chemistry and preventive care. 

In 2021, it was acquired by PharmEasy for INR 4,546 Cr. PharmEasy parent API Holdings owns a 66.1% stake in the company. 

Going ahead, the company plans to expand its operations in international markets, starting with Tanzania.